Medicine for treating or preventing cancer
A combination therapy with Compound 1 and molecular targeting agents like EGFR or MEK inhibitors addresses the limitations of current anticancer drugs by enhancing RAS signaling inhibition and cell growth suppression, effectively treating cancers with RAS gene abnormalities.
Patent Information
- Application Number
- JP2024135111
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-19
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current anticancer drugs, including molecular targeting agents, have limitations in efficacy for treating or preventing cancer, necessitating the development of more effective medicines.
A combination therapy using a first active ingredient, represented by Compound 1, and a second active ingredient such as a molecular targeting agent or a MAPK/ERK pathway inhibitor, including EGFR, VEGF, SHP2, KRAS-G12C, or MEK inhibitors, to enhance cancer treatment or prevention.
The combination therapy significantly enhances the inhibition of RAS signaling and cell growth, demonstrating improved efficacy in treating various cancers, particularly those with RAS gene abnormalities, by simultaneously targeting multiple pathways.
Smart Images

Figure 2024161461000042 
Figure 2024161461000043 
Figure 2024161461000044
Abstract
Description
[Technical field]
[0001] The present invention relates to a medicine for treating or preventing cancer. [Background technology]
[0002] Cancer is a disease in which cells grow uncontrollably due to abnormalities in genes. Chemotherapy is a medical treatment for cancer, and various anticancer drugs are used. In recent years, many molecular targeted agents that act specifically on molecules that are specifically expressed in certain cancer cells or molecules whose expression is enhanced in cancer cells have been developed as anticancer drugs. Known molecular targeted agents include antibody drugs such as cetuximab, bevacizumab, and panitumumab (Patent Document 1), and small molecule drugs such as gefitinib, erlotinib, and afatinib (Patent Document 2). Furthermore, medium molecule drugs have also been known in recent years (Patent Document 3). [Prior art documents] [Patent documents]
[0003] [Patent Document 1] JP 2018-076369 A [Patent Document 2] Patent Publication No. 2021-063014 [Patent Document 3] International Publication No. 2021 / 090855 Summary of the Invention [Problem to be solved by the invention]
[0004] Under these circumstances, there is a current demand for medicines with even greater efficacy in treating or preventing cancer.
[0005] Therefore, an object of the present invention is to provide a pharmaceutical agent that is more effective in treating or preventing cancer than ever before. [Means for solving the problem]
[0006] The present invention includes the following [1] to
[94] . [1] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a compound represented by the following formula (1) (hereinafter also referred to as "Compound 1") or a salt thereof, or a solvate thereof, and the second active ingredient is a molecular targeted agent. [ka] [2] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a molecular targeted agent, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof. [3] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a MAPK / ERK pathway inhibitor. [4] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a MAPK / ERK pathway inhibitor, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof. [5] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor. [6] A pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor and a MEK inhibitor, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof. [7] The pharmaceutical according to any of [1] to [6], wherein the first active ingredient and the second active ingredient are provided as a kit. [8] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a molecular targeted agent. [9] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is a molecular targeted agent, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[10] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a MAPK / ERK pathway inhibitor.
[11] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is a MAPK / ERK pathway inhibitor, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[12] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor.
[13] A method for treating or preventing cancer, comprising administering a first active ingredient and a second active ingredient to a subject, wherein the first active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor and a MEK inhibitor, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[14] A first active ingredient for use in the treatment or prevention of cancer, in combination with a second active ingredient, wherein the first active ingredient is Compound 1 or a salt thereof or a solvate thereof, and the second active ingredient is a molecular targeted agent.
[15] A first active ingredient for use in the treatment or prevention of cancer, in combination with a second active ingredient, wherein the first active ingredient is a molecular targeted agent and the second active ingredient is Compound 1 or a salt thereof, or a solvate thereof.
[16] A first active ingredient for use in the treatment or prevention of cancer, in combination with a second active ingredient, wherein the first active ingredient is Compound 1 or a salt thereof or a solvate thereof, and the second active ingredient is a MAPK / ERK pathway inhibitor.
[17] A first active ingredient for use in the treatment or prevention of cancer, in combination with a second active ingredient, wherein the first active ingredient is a MAPK / ERK pathway inhibitor and the second active ingredient is Compound 1 or a salt thereof, or a solvate thereof.
[18] A first active ingredient for use in the treatment or prevention of cancer in combination with a second active ingredient, wherein the first active ingredient is Compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor.
[19] A first active ingredient for use in the treatment or prevention of cancer, in combination with a second active ingredient, wherein the first active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor and a MEK inhibitor, and the second active ingredient is Compound 1 or a salt thereof, or a solvate thereof.
[20] Use of a first active ingredient in combination with a second active ingredient for the manufacture of a medicament for treating or preventing cancer, wherein the first active ingredient is Compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a molecular targeted agent.
[21] Use of a first active ingredient in combination with a second active ingredient for the manufacture of a medicament for treating or preventing cancer, wherein the first active ingredient is a molecular targeted agent and the second active ingredient is Compound 1 or a salt thereof, or a solvate thereof.
[22] Use of a first active ingredient in the manufacture of a medicament for treating or preventing cancer in combination with a second active ingredient, wherein the first active ingredient is Compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a MAPK / ERK pathway inhibitor.
[23] Use of a first active ingredient in combination with a second active ingredient for the manufacture of a medicament for treating or preventing cancer, wherein the first active ingredient is a MAPK / ERK pathway inhibitor and the second active ingredient is Compound 1 or a salt thereof, or a solvate thereof.
[24] Use of a first active ingredient in the manufacture of a medicament for treating or preventing cancer in combination with a second active ingredient, wherein the first active ingredient is Compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor.
[25] Use of a first active ingredient in the manufacture of a medicament for treating or preventing cancer in combination with a second active ingredient, wherein the first active ingredient is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor and a MEK inhibitor, and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[26] The first active ingredient and the second active ingredient are administered in combination simultaneously or separately (i.e., the first active ingredient and the second active ingredient are administered in combination simultaneously or separately), a first active ingredient for use, or a use described in any of [1] to
[25] .
[27] The first active ingredient for use, or the use, according to any one of [1] to
[26] , wherein the first active ingredient and the second active ingredient are used together as a combination drug.
[28] The first active ingredient for the medicament, method, use, or use described in any of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] and
[27] , wherein the molecular targeted agent is a MAPK / ERK pathway inhibitor.
[29] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] and
[28] , wherein the molecular targeted agent is at least one selected from the group consisting of EGFR inhibitors, VEGF inhibitors, SHP2 inhibitors, KRAS-G12C inhibitors and MEK inhibitors.
[30] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] and
[29] , wherein the molecular targeted agent is an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor or a MEK inhibitor.
[31] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] ,
[29] and
[30] , wherein the molecular targeted agent is an EGFR inhibitor.
[32] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] ,
[29] and
[30] , wherein the molecular targeted agent is a VEGF inhibitor.
[33] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] ,
[29] and
[30] , wherein the molecular targeted agent is an SHP2 inhibitor.
[34] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] ,
[29] and
[30] , wherein the molecular targeted agent is a KRAS-G12C inhibitor.
[35] The first active ingredient for the medicament, method, use, or use according to any one of [1], [2], [7], [8], [9],
[14] ,
[15] ,
[20] ,
[21] ,
[26] ,
[27] ,
[28] ,
[29] and
[30] , wherein the molecular targeted agent is a MEK inhibitor.
[36] The first active ingredient for the medicament, method, use, or use according to [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] ,
[29] ,
[30] and
[31] , wherein the EGFR inhibitor is at least one selected from the group consisting of gefitinib, erlotinib, afatinib, osimertinib, lapatinib, or a salt or solvate thereof, and an anti-EGFR antibody.
[37] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] ,
[29] ,
[30] ,
[31] and
[36] , wherein the EGFR inhibitor is an anti-EGFR antibody.
[38] The first active ingredient for the medicine, method, use, or use described in
[36] or
[37] , wherein the anti-EGFR antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2.
[39] The first active ingredient for the pharmaceutical, method, use, or use according to any one of
[36] to
[38] , wherein the anti-EGFR antibody is cetuximab.
[40] The first active ingredient for the pharmaceutical, method, use, or use described in any of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[39] , wherein the VEGF inhibitor is at least one selected from the group consisting of sorafenib, pazopanib, sunitinib, axitinib, regorafenib, or a salt or solvate thereof, and an anti-VEGF antibody.
[41] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[40] , wherein the VEGF inhibitor is an anti-VEGF antibody.
[42] The first active ingredient for the pharmaceutical, method, use, or use described in
[40] or
[41] , wherein the anti-VEGF antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4.
[43] The pharmaceutical, method, first active ingredient for use, or use according to any of
[40] to
[42] , wherein the anti-VEGF antibody is bevacizumab.
[44] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[43] , wherein the SHP2 inhibitor is at least one selected from the group consisting of RMC4550, TNO155, RLY1971, SHP099, NSC-87877, and salts and solvates thereof.
[45] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[44] , wherein the SHP2 inhibitor is at least one selected from the group consisting of RMC4550, TNO155, and salts and solvates thereof.
[46] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[45] , wherein the SHP2 inhibitor is RMC4550 or a salt thereof, or a solvate thereof. [46-1] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[45] , wherein the SHP2 inhibitor is TNO155 or a salt thereof, or a solvate thereof.
[47] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[46] , wherein the KRAS-G12C inhibitor is at least one selected from the group consisting of sotorasib, MRTX849, and salts and solvates thereof.
[48] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[47] , wherein the KRAS-G12C inhibitor is sotorasib. [48-1] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[47] , wherein the KRAS-G12C inhibitor is MRTX849.
[49] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[47] , wherein the KRAS-G12C inhibitor is sotorasib or a salt thereof, or a solvate thereof. [49-1] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[47] , wherein the KRAS-G12C inhibitor is MRTX849 or a salt thereof, or a solvate thereof.
[50] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[49] , wherein the MEK inhibitor is at least one selected from the group consisting of compounds represented by the following formula (2), trametinib, selumetinib, CH4987655, and salts thereof and solvates thereof: [ka]
[51] The above-mentioned MEK inhibitor is a compound represented by the following formula (2), trametinib, or a salt or solvate thereof, or the first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[50] . [ka]
[52] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[51] , wherein the MEK inhibitor is a compound represented by the following formula (2) or a salt thereof, or a solvate thereof:
[53] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] and
[29] to
[51] , wherein the MEK inhibitor is trametinib or a salt thereof, or a solvate thereof.
[54] The first active ingredient for the medicament, method, use, or use according to any one of [5], [6], [7],
[12] ,
[13] ,
[18] ,
[19] ,
[24] ,
[25] ,
[26] ,
[27] ,
[29] to
[51] and
[53] , wherein the MEK inhibitor is trametinib dimethyl sulfoxide adduct.
[55] The first active ingredient for the medicine, method, use, or use according to any one of [1] to
[54] , wherein compound 1 or a salt thereof, or a solvate thereof is a solvate of compound 1.
[56] The first active ingredient for the medicament, method, use, or use according to
[55] , wherein the solvate is a hydrate.
[57] The first active ingredient for the medicine, method, use, or use according to any one of [1] to
[54] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1.
[58] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the EGFR inhibitor is cetuximab.
[59] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the VEGF inhibitor is an anti-VEGF antibody.
[60] The first active ingredient for the medicament, method, use, or use according to
[59] , wherein the anti-VEGF antibody is bevacizumab.
[61] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is RMC4550 or a salt thereof, or a solvate thereof. [61-1] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is TNO155 or a salt thereof, or a solvate thereof.
[62] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is RLY1971 or a salt thereof, or a solvate thereof.
[63] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the KRAS-G12C inhibitor is sotorasib or a salt thereof, or a solvate thereof. [63-1] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the KRAS-G12C inhibitor is MRTX849 or a salt thereof, or a solvate thereof.
[64] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the MEK inhibitor is a compound represented by the following formula (2) or a salt thereof, or a solvate thereof:
[65] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is a hydrate of compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the MEK inhibitor is trametinib or a salt thereof, or a solvate thereof.
[66] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the EGFR inhibitor is cetuximab.
[67] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the M APK / ERK pathway inhibitor, or the VEGF inhibitor is an anti-VEGF antibody.
[68] The first active ingredient for the medicament, method, use, or use according to
[67] , wherein the anti-VEGF antibody is bevacizumab.
[69] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is RMC4550 or a salt thereof, or a solvate thereof. [69-1] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is TNO155 or a salt thereof, or a solvate thereof.
[70] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the SHP2 inhibitor is RLY1971 or a salt thereof, or a solvate thereof.
[71] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the KRAS-G12C inhibitor is sotorasib or a salt thereof, or a solvate thereof. [71-1] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the KRAS-G12C inhibitor is MRTX849 or a salt thereof, or a solvate thereof.
[72] A first active ingredient for a pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the MEK inhibitor is a compound represented by formula (2) or a salt thereof, or a solvate thereof.
[73] The first active ingredient for the pharmaceutical, method, use, or use according to any of [1] to
[25] , wherein compound 1 or a salt thereof, or a solvate thereof is compound 1, and the molecular targeted agent, the MAPK / ERK pathway inhibitor, or the MEK inhibitor is trametinib or a salt thereof, or a solvate thereof.
[74] The first active ingredient for the pharmaceutical, method, use, or use described in any of [1] to
[73] , wherein the cancer is a solid cancer or a blood cancer.
[75] The first active ingredient for the pharmaceutical, method, use, or use described in any of [1] to
[74] , wherein the cancer is at least one selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.
[76] The above cancer is a cancer associated with an abnormality in the RAS gene or the MAPK / ERK pathway (an abnormality in a protein in the MAPK / ERK pathway or a gene that produces the protein), the first active ingredient for the pharmaceutical, method, use, or use described in any of [1] to
[75] .
[77] The pharmaceutical, method, first active ingredient for use, or use according to any of [1] to
[76] , wherein the abnormality in the MAPK / ERK pathway is abnormal activation of the MAPK / ERK pathway.
[78] The first active ingredient for use, or use, of any of [1] to
[77] , wherein the abnormality in the MAPK / ERK pathway is abnormal activation due to amplification of a protein in the MAPK / ERK pathway.
[79] The first active ingredient for use, or use according to any of [1] to
[78] , wherein the abnormality in the MAPK / ERK pathway is abnormal activation due to a genetic mutation in the MAPK / ERK pathway.
[80] The first active ingredient for use, or use according to any of [1] to
[79] , wherein the cancer is a cancer associated with an abnormality in the RAS gene.
[81] The medicine, method, first active ingredient for use, or use according to
[80] , wherein the abnormality in the RAS gene is a mutation in the coding region of the RAS gene and / or an amplification of the copy number of the RAS gene.
[82] The pharmaceutical, method, first active ingredient for use, or use described in any of
[76] to
[81] , wherein the RAS gene is at least one RAS gene selected from the group consisting of the KRAS gene, the NRAS gene, and the HRAS gene.
[83] The first active ingredient for the pharmaceutical, method, use, or use according to any one of
[76] to
[82] , wherein the RAS gene is the KRAS gene.
[84] A first active ingredient for use, or a pharmaceutical agent, method, or use according to any one of [1] to
[83] , wherein cancer is associated with the production of mutant RAS proteins and / or increased production of RAS proteins.
[85] A first active ingredient for a medicine, method, use, or use according to any one of [1] to
[84] , wherein cancer is associated with the production of mutant RAS protein.
[86] The first active ingredient for the pharmaceutical, method, use, or use described in
[84] or
[85] , wherein the mutant RAS protein is one or more mutant RAS proteins selected from the group consisting of mutant KRAS protein, mutant NRAS protein, and mutant HRAS protein.
[87] The first active ingredient for use, or use described in any of
[84] to
[86] , wherein the mutant RAS protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61.
[88] The pharmaceutical, method, first active ingredient for use, or use described in any of
[84] to
[87] , wherein the mutant RAS protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13 and Q61 (excluding the G12D mutation).
[89] The first active ingredient for the pharmaceutical, method, use, or use according to any one of
[84] to
[88] , wherein the mutant RAS protein is a mutant KRAS protein.
[90] The first active ingredient for use, or use, of any of
[84] to
[89] , wherein the mutant RAS protein is a mutant KRAS protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K.
[91] The first active ingredient for use, or use, of any of
[84] to
[90] , wherein the mutant RAS protein is a mutant KRAS protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12S, G12V, G13D, Q61H, and Q61K.
[92] The first active ingredient for use, or use, of any of
[84] to
[88] , wherein the mutant RAS protein is a mutant NRAS protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L.
[93] The first active ingredient for the pharmaceutical, method, use, or use described in any of
[84] to
[88] and
[92] , wherein the mutant RAS protein is a mutant NRAS protein and has at least one amino acid mutation selected from the group consisting of G12C, G13D, G13V, Q61K, and Q61L.
[94] The first active ingredient for use, or use, of any of
[84] to
[88] , wherein the mutant RAS protein is a mutant HRAS protein and has an amino acid mutation of G13R. Effect of the Invention
[0007] According to the present invention, there is provided a medicine which is more effective in treating or preventing cancer than ever before. [Brief description of the drawings]
[0008] [Figure 1] Fig. 1 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and sotorasib using NCI-H358 in Example 1. More specifically, Fig. 1 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, NRAS, HRAS, KRAS-GTP, NRAS-GTP, HRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H358. [Diagram 2] Figure 2 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and sotorasib using NCI-H1373 in Example 1. More specifically, Figure 2 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, NRAS, HRAS, KRAS-GTP, NRAS-GTP, HRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H1373. [Diagram 3] Fig. 3 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and RMC-4550 (RMC) using NCI-H441 in Example 1. More specifically, Fig. 3 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, NRAS, HRAS, KRAS-GTP, NRAS-GTP, HRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H441. [Figure 4]Fig. 4 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and trametinib (trame) using NCI-H441 in Example 1. More specifically, Fig. 4 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, NRAS, HRAS, KRAS-GTP, NRAS-GTP, HRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H441. [Diagram 5] Fig. 5 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and Compound 2 using NCI-H358 in Example 1. More specifically, Fig. 5 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, KRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H358. [Figure 6] Fig. 6 is a diagram showing the results of evaluating the RAS signal inhibitory activity of the combined use of Compound 1 and Compound 2 using NCI-H441 in Example 1. More specifically, Fig. 6 is an electrophoretic image showing the results of Western blotting of proteins (KRAS, KRAS-GTP, ERK, AKT, MEK, pERK, pAKT, and pMEK) extracted from NCI-H441. [Figure 7] FIG. 7 is a diagram showing the results of cell growth inhibitory activity evaluation of the combined use of compound 1 and RMC-4550 using NCI-H358 in Example 2. The horizontal axis of FIG. 7a represents the concentration of RMC-4550, and the vertical axis represents the concentration of compound 1. Each cell in FIG. 7a shows GI (Growth Inhibition, growth inhibition rate (%)) at each concentration. The horizontal axis of FIG. 7b represents the value obtained by dividing the concentration of RMC-4550 by the concentration (0.55 μM) at which RMC-4550 alone gives GI155, and the vertical axis represents the value obtained by dividing the concentration of compound 1 by the concentration (0.033 μM) at which compound 1 alone gives GI155. The concentration at which GI155 is given when RMC-4550 and compound 1 are used in combination was measured and plotted in the graph of FIG. 7b. [Figure 8]FIG. 8 is a diagram showing the results of cell proliferation inhibitory activity evaluation of the combined use of compound 1 and RMC-4550 using NCI-H441 in Example 2. The horizontal axis of FIG. 8a represents the concentration of RMC-4550, and the vertical axis represents the concentration of compound 1. Each cell of FIG. 8a shows the GI (%) at each concentration. The horizontal axis of FIG. 8b represents the value obtained by dividing the concentration of RMC-4550 by the concentration (0.35 μM) at which RMC-4550 alone gives GI100, and the vertical axis represents the value obtained by dividing the concentration of compound 1 by the concentration (0.0055 μM) at which compound 1 alone gives GI100. The concentration at which GI100 is given when RMC-4550 and compound 1 are used in combination is measured and plotted in the graph of FIG. 8b. [Figure 9] FIG. 9 is a diagram showing the results of cell proliferation inhibitory activity evaluation of the combination of Compound 1 and Trametinib using NCI-H358 in Example 2. The horizontal axis of FIG. 9a represents the concentration of Trametinib, and the vertical axis represents the concentration of Compound 1. Each cell of FIG. 9a shows the GI (%) at each concentration. The horizontal axis of FIG. 9b represents the value obtained by dividing the concentration of Trametinib by the concentration (0.00035 μM) at which GI50 is given by Trametinib alone, and the vertical axis represents the value obtained by dividing the concentration of Compound 1 by the concentration (0.0046 μM) at which GI50 is given by Compound 1 alone. The concentration at which GI50 is given when Trametinib and Compound 1 are used in combination was measured and plotted on the graph of FIG. 9b. [Figure 10] 10 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and Cetuximab using LoVo in Example 3. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days after cell transplantation. [Figure 11] Figure 11 shows the results of in vivo RAS signal inhibitory activity evaluation in Example 4. "Cetu" in the figure means cetuximab. More specifically, Figure 11 shows electrophoretic images showing the results of Western blotting of proteins (KRAS, KRAS-GTP, ERK, AKT, EGFR, pERK, pAKT, and pEGFR) extracted from the tumor cells in Example 4. [Figure 12]12 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and Bevacizumab using AsPC-1 (pancreatic cancer: KRAS G12D mutant strain) in Example 5. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days after cell transplantation. [Figure 13] FIG. 13 shows the results of evaluating the cell proliferation inhibitory activity of the combined use of Compound 1 and sotorasib using SW837 in Example 6. [Figure 14] FIG. 14 shows the results of evaluating the cell proliferation inhibitory activity of the combined use of Compound 1 and MRTX849 using HCC-1171 and NCI-H1373 in Example 7. [Figure 15] FIG. 15 shows the results of evaluating the cell proliferation inhibitory activity of the combined use of Compound 1 and TNO155 using HCC-1171, NCI-H23, NCI-H1373 and UM-UC-3 in Example 7. [Figure 16] 16 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and sotorasib using CTG-2579 (lung cancer: KRAS G12C mutant strain) in Example 8. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days elapsed since the start of administration, with the start of administration being day 0. [Figure 17] Fig. 17 shows the results of in vivo RAS signal inhibitory activity evaluation in Example 9. More specifically, Fig. 17 shows electrophoretic images showing the results of Western blotting of proteins (KRAS, KRAS-GTP, ERK, pERK, AKT, and pAKT) extracted from the tumor cells of Example 9. [Figure 18] 18 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and MRTX849 using LU65 (lung cancer: KRAS G12C mutant strain) and UM-UC-3 (bladder cancer: KRAS G12C mutant strain) in Example 10. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days after cell transplantation. [Figure 19]19 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and TNO155 using NCI-H1373 (lung cancer: KRAS G12C mutant strain) in Example 11. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days elapsed since the start of administration, with the start of administration being day 0. [Figure 20] 20 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and Compound 2 using NCI-H441 (lung cancer: KRAS G12V mutant strain) in Example 12. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days after cell transplantation. [Figure 21] 21 is a diagram showing the results of in vivo antitumor activity evaluation of the combined use of Compound 1 and Compound 2 using NCI-H1373 (lung cancer: KRAS G12C mutant strain) in Example 12. The vertical axis represents the tumor volume, and the horizontal axis represents the number of days elapsed since the start of administration, with the start of administration being set as day 0. [Figure 22] Fig. 22 shows the results of in vivo RAS signal inhibitory activity evaluation in Example 13. More specifically, Fig. 22 shows electrophoretic images showing the results of Western blotting of proteins (KRAS, KRAS-GTP, ERK, pERK, AKT, pAKT, MEK, and pMEK) extracted from the tumor cells of Example 13. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] An embodiment of the present invention will be described. However, the present invention is not limited to the following embodiment. The therapeutic or preventive medicine and therapeutic or preventive method of the present invention may be administered or applied to humans. In this specification, the term "to" indicating a range includes both ends, for example, "A to B" means a range of A or more and B or less. In this specification, the term "about" means a range of +10% and -10% of the numerical value when used in combination with a numerical value. In the present invention, the meaning of the term "and / or" includes any combination of "and" and "or" appropriately combined. Specifically, for example, "A, B, and / or C" includes the following seven variations; (i) A, (ii) B, (iii) C, (iv) A and B, (v) A and C, (vi) B and C, (vii) A, B, and C.
[0010] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, which comprises a first active ingredient and is used in combination with a second active ingredient, wherein the first active ingredient is a compound represented by the following formula (1) (hereinafter also referred to as "compound 1") or a salt thereof, or a solvate thereof, and the second active ingredient is a molecular targeted agent. [ka]
[0011] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a molecular targeted agent and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0012] In order to use compound 1 or a salt thereof or a solvate thereof in combination with a molecular targeting agent, compound 1 or a salt thereof or a solvate thereof of the present invention can be used as either a first active ingredient or a second active ingredient, and the molecular targeting drug of the present invention can be used as either a first active ingredient or a second active ingredient. Preferably, the molecular targeting agent is a MAPK / ERK pathway inhibitor. More preferably, the molecular targeting agent is one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, a SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor.
[0013] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a MAPK / ERK pathway inhibitor.
[0014] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a MAPK / ERK pathway inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0015] In order to use compound 1 or a salt thereof, or a solvate thereof in combination with a MAPK / ERK pathway inhibitor, compound 1 or a salt thereof, or a solvate thereof described in this embodiment can be used as either a first active ingredient or a second active ingredient, and the MAPK / ERK pathway inhibitor described in this embodiment can be used as either a first active ingredient or a second active ingredient.
[0016] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is an EGFR inhibitor.
[0017] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is an EGFR inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0018] In order to use compound 1 or a salt thereof or a solvate thereof in combination with an EGFR inhibitor, compound 1 or a salt thereof or a solvate thereof described in this embodiment can be used as either a first active ingredient or a second active ingredient, and the EGFR inhibitor described in this embodiment can be used as either a first active ingredient or a second active ingredient. The EGFR inhibitor may be at least one selected from the group consisting of gefitinib, erlotinib, afatinib, osimertinib, lapatinib, or a salt thereof or a solvate thereof and an anti-EGFR antibody, and may be an anti-EGFR antibody. Preferably, the EGFR inhibitor may be an anti-EGFR antibody. The anti-EGFR antibody may have a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2, and may be cetuximab. More preferably, the EGFR inhibitor may be cetuximab.
[0019] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a VEGF inhibitor.
[0020] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient in combination with a second active ingredient, wherein the first active ingredient is a VEGF inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0021] Compound 1 or its salt or solvate thereof described in this embodiment can be used as either the first active ingredient or the second active ingredient, and the VEGF inhibitor described in this embodiment can be used as either the first active ingredient or the second active ingredient, so that compound 1 or its salt or solvate thereof is used in combination with a VEGF inhibitor. The VEGF inhibitor may be at least one selected from the group consisting of sorafenib, pazopanib, sunitinib, axitinib, regorafenib, or their salts or solvates, and anti-VEGF antibodies, may be an anti-VEGF antibody, may have a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, and may be bevacizumab, ramucirumab, or aflibercept. As the VEGF inhibitor, an anti-VEGF antibody is preferable, and bevacizumab is more preferable.
[0022] One embodiment of the present invention is a medicament for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is an SHP2 inhibitor.
[0023] Another embodiment of the present invention is a medicament for treating or preventing cancer, comprising a first active ingredient in combination with a second active ingredient, wherein the first active ingredient is an SHP2 inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0024] In order to use compound 1 or a salt thereof or a solvate thereof in combination with an SHP2 inhibitor, compound 1 or a salt thereof or a solvate thereof described in this embodiment can be used as either a first active ingredient or a second active ingredient, and the SHP2 inhibitor described in this embodiment can be used as either a first active ingredient or a second active ingredient. The SHP2 inhibitor may be at least one selected from the group consisting of RMC4550, TNO155, RLY1971, SHP099, NSC-87877, and salts thereof and solvates thereof, and preferably, the SHP2 inhibitor may be RMC4550, RLY1971, TNO155, or salts thereof, or solvates thereof. More preferably, the SHP2 inhibitor is RMC4550, TNO155, or salts thereof, or solvates thereof.
[0025] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a KRAS-G12C inhibitor.
[0026] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is a KRAS-G12C inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0027] In order to use compound 1 or its salt or its solvate in combination with a KRAS-G12C inhibitor, compound 1 or its salt or its solvate described in this embodiment can be used as either the first active ingredient or the second active ingredient, and the KRAS-G12C inhibitor described in this embodiment can be used as either the first active ingredient or the second active ingredient. The KRAS-G12C inhibitor may be at least one selected from the group consisting of sotorasibe, MRTX849, and their salts and solvates thereof, and is preferably sotorasibe, MRTX849, or their salts or solvates thereof.
[0028] One embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, wherein the first active ingredient is compound 1 or a salt thereof, or a solvate thereof, and the second active ingredient is a MEK inhibitor.
[0029] Another embodiment of the present invention is a pharmaceutical for treating or preventing cancer, comprising a first active ingredient in combination with a second active ingredient, wherein the first active ingredient is a MEK inhibitor and the second active ingredient is compound 1 or a salt thereof, or a solvate thereof.
[0030] Compound 1 or its salt or its solvate can be used in combination with a MEK inhibitor, and compound 1 or its salt or its solvate described in this embodiment can be used as either the first active ingredient or the second active ingredient, and the MEK inhibitor described in this embodiment can be used as either the first active ingredient or the second active ingredient. The MEK inhibitor can be at least one selected from the group consisting of the compound represented by the following formula (2), trametinib, selumetinib, CH4987655, and their salts and solvates thereof, and preferably, the compound represented by formula (2), trametinib, or their salts or their solvates. More preferably, the MEK inhibitor can be the compound represented by formula (2), or its salt, or their solvates.
[0031] The first active ingredient and the second active ingredient may be provided as a kit. A further embodiment of the present invention may be a kit containing the first active ingredient and the second active ingredient. The medicament of the present invention may be provided as a kit. Another embodiment of the present invention may be a kit containing the medicament.
[0032] "Combined use" means that active ingredients are used in combination. For example, combined use of a first active ingredient and a second active ingredient includes "administration as a single preparation containing the first active ingredient and the second active ingredient" (i.e., the first active ingredient and the second active ingredient are combined as a combination drug (combined drug)) and "administration of the first active ingredient and the second active ingredient simultaneously or separately as separate preparations." In the latter embodiment, the preparation containing the first active ingredient may be administered first, or the preparation containing the second active ingredient may be administered first. The latter embodiment may be any of the following: "the first active ingredient and the second active ingredient are formulated separately and administered simultaneously via the same administration route", "the first active ingredient and the second active ingredient are formulated separately and administered separately via the same administration route with a time lag", "the first active ingredient and the second active ingredient are formulated separately and administered simultaneously via different administration routes (administered from different sites of the same patient)", and "the first active ingredient and the second active ingredient are formulated separately and administered separately via different administration routes with a time lag". In the "embodiment in which the first active ingredient and the second active ingredient are formulated separately and administered simultaneously via the same administration route", both drugs (the drug containing the first active ingredient and the drug containing the second active ingredient) may be mixed immediately before administration. "Separately" means that one formulation is administered before or after administration of the other formulation.
[0033] In other words, "combination use" can be said to be a method of use in which one active ingredient is present in the patient's body while the other active ingredient is present in the patient's body. That is, a preferred embodiment is one in which the first active ingredient and the second active ingredient are administered so that they are simultaneously present in the patient's body, for example, in the blood, and a preferred embodiment is one in which a drug containing the first active ingredient and a drug containing the second active ingredient are administered to the patient simultaneously, or another drug containing the first active ingredient or the second active ingredient is administered to the patient within 48 hours after administration of the other drug.
[0034] Compound 1 or a salt thereof, or a solvate thereof may be Compound 1, a solvate of Compound 1, or a hydrate of Compound 1.
[0035] Examples of the salt of compound 1 include pharmaceutically acceptable salts, specifically, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid; salts with organic acids such as acetic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, stearic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, and p-toluenesulfonic acid; salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; salts with amino acids such as arginine, and the like. These salts are produced, for example, by contacting the compound with an acid or base. In this specification, the solvate is not particularly limited as long as it forms a single molecular group together with the solvent, but is a solvate formed with a solvent that can be taken (ingested) with the administration of a drug. For example, solvates with a single solvent such as hydrate, alcohol hydrate (ethanol hydrate, methanol hydrate, 1-propanol hydrate, 2-propanol hydrate, etc.), dimethyl sulfoxide, etc., as well as solvates with multiple solvents for one molecule of a compound, and solvates with multiple types of solvents for one molecule of a compound can be mentioned. When the solvent is water, it is called a hydrate. A solvate is produced, for example, by contacting a compound with a solvent, and a solvate of a salt is produced, for example, by contacting a compound salt with a solvent. A salt of a compound or a solvate of a compound or a salt of a compound are all active forms, just like the compound (free form). In this specification, "(their) solvates" includes a solvate of compound 1, a solvate of a molecular targeted agent, a solvate of a salt of compound 1, and a solvate of one salt of a molecular targeted agent.
[0036] Compound 1 or its salt or solvate thereof may have a crystalline polymorphism, but may be a single crystal form or a mixture of crystal forms. Compound 1 or its salt or solvate thereof also includes amorphous forms.
[0037] The dosage of compound 1 or a salt thereof or a solvate thereof is preferably 0.001-100 mg (0.001-100 mg / kg / day) per kg of the body weight of the subject to be administered, more preferably 0.003-20 mg / kg / day, and even more preferably 0.003-10 mg / kg / day. When the dosage of compound 1 is within these ranges, the effect of treating or preventing cancer is further enhanced. The number of times that compound 1 is administered can be, for example, once a day, twice a day, or three times a day, with once a day being more preferred. The same dosage and / or method of administration can be applied to molecular targeting agents.
[0038] Compound 1 can be produced, for example, according to the method described in WO 2021 / 090855, peptide synthesis using the Fmoc method, or solid phase peptide synthesis (published by Bachem, [Retrieved December 24, 2021], Internet URL: https: / / www.bachem.com / wp-admin / admin-ajax.php?juwpfisadmin=false&action=wpfd&task=file.download&wpfd_category_id=180&wpfd_file_id=213455&token=&preview=1, or Peptide Guide, No: 2004505, published by Global Marketing Bachem AG, 2020.).
[0039] In the present specification, the term "molecularly targeted agent" refers to an agent having an antitumor effect and specifically inhibiting a specific protein. In the present specification, compound 1 or a salt thereof, or a solvate thereof is not included in the molecularly targeted agent. Examples of molecularly targeted agents include MAPK / ERK pathway inhibitors, which can be used as medicines for treating or preventing cancer. In the present specification, the term "MAPK / ERK pathway inhibitors" refers to inhibitors of targets involved in MAPK / ERK signaling, and includes inhibitors of growth factors and their receptors, as well as kinase inhibitors. For example, examples of MAPK / ERK pathway inhibitors include EGFR inhibitors, VEGF inhibitors, SHP2 inhibitors, KRAS inhibitors, NRAS inhibitors, HRAS inhibitors, KRAS-GTP inhibitors, NRAS-GTP inhibitors, HRAS-GTP inhibitors, KRAS-G12C inhibitors, ERK inhibitors, AKT inhibitors, and MEK inhibitors. The molecular targeting agent may be at least one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor, and may be an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, or a MEK inhibitor. Preferably, the molecular targeting agent is an EGFR inhibitor. The EGFR inhibitor may be at least one selected from the group consisting of gefitinib, erlotinib, afatinib, osimertinib, lapatinib, or a salt thereof or a solvate thereof, and an anti-EGFR antibody, and may be an anti-EGFR antibody. Preferably, the EGFR inhibitor is an anti-EGFR antibody. The anti-EGFR antibody may have a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2, and may be cetuximab. More preferably, the EGFR inhibitor is cetuximab. The VEGF inhibitor may be at least one selected from the group consisting of sorafenib, pazopanib, sunitinib, axitinib, regorafenib or a salt or solvate thereof, and an anti-VEGF antibody, may be an anti-VEGF antibody, may have a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, and may be bevacizumab, ramucirumab, or aflibercept.The VEGF inhibitor is preferably an anti-VEGF antibody, more preferably bevacizumab. The SHP2 inhibitor may be at least one selected from the group consisting of RMC4550, TNO155, RLY1971, SHP099, NSC-87877, their salts and their solvates, or may be RMC4550, TNO155, their salts and their solvates. Preferably, the SHP2 inhibitor may be one selected from the group consisting of RMC4550, TNO155, RLY1971, their salts and their solvates. More preferably, the SHP2 inhibitor may be RMC4550, TNO155, their salts or their solvates. The KRAS-G12C inhibitor may be at least one selected from the group consisting of sotorasib, MRTX849, and their salts and solvates thereof, and preferably sotorasib or its salt or its solvate, or MRTX849 or its salt or its solvate. The MEK inhibitor may be at least one selected from the group consisting of a compound represented by the following formula (2), trametinib, selumetinib, CH4987655, and their salts and solvates thereof, and preferably a compound represented by the following formula (2), trametinib or their salts or their solvates. More preferably, the MEK inhibitor may be a compound represented by the following formula (2), or its salt, or its solvate. [ka]
[0040] Molecular targeting agents can be obtained from commercial suppliers or prepared according to known methods.
[0041] Gefitinib (CAS number: 184475-35-2, N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine) is a compound represented by the following formula (3). Gefitinib is used as Iressa. [ka]
[0042] Erlotinib (CAS number: 183321-74-6, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine) is a compound represented by the following formula (4). Erlotinib is used as erlotinib hydrochloride or Tarceva. [ka]
[0043] Afatinib (CAS number: 439081-18-2, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide) is a compound represented by the following formula (5). Afatinib is used as afatinib maleate or diotriflamide. [ka]
[0044] Osimertinib (CAS number: 1421373-65-0, N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide is a compound represented by the following formula (6). Osimertinib is used as osimertinib mesylate or Tagrisso. [ka]
[0045] Lapatinib (CAS number: 231277-92-2, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine is a compound represented by the following formula (7). Lapatinib is used as lapatinib tosylate hydrate or Tykerb. [ka]
[0046] RMC-4550 (CAS number: 2172651-73-7, 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]dec-8-yl]-6-(2,3-dichlorophenyl)-5-methyl-2-pyrazinemethanol) is a compound represented by the following formula (8). [ka]
[0047] TNO155 (CAS number: 1801765-04-7, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine) is a compound represented by the following formula (9). [ka]
[0048] RLY1971 is a compound represented by CAS number: 2668298-71-1.
[0049] SHP099 (CAS number: 1801747-42-1, 6-(4-amino-4-methyl-1-piperidinyl)-3-(2,3-dichlorophenyl)-2-pyrazineamine) is a compound represented by the following formula (10). [ka]
[0050] NSC-87877 (CAS number: 56990-57-9, 8-hydroxy-7-[2-(6-sulfo-2-naphthalenyl)diazenyl]-5-quinolinesulfonic acid) is a compound represented by the following formula (11). [ka]
[0051] Sotorasib (CAS number: 2296729-00-3, 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one is a compound represented by the following formula (12). Sotorasib is used as AMG510 or Lumakras. [ka]
[0052] MRTX849 (CAS number: 2326521-71-3, 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile is a compound represented by the following formula (13). MRTX849 is used as adagrasib. [ka]
[0053] Trametinib (CAS number: 871700-17-3, N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide is a compound represented by the following formula (14). Trametinib is used as trametinib dimethyl sulfoxide adduct or Mekinist. [ka]
[0054] Compound 2 (CAS number: 2677856-11-8, 2-(4-cyclopropyl-2-fluoro-anilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]benzamide, 2-(4-cyclopropyl-2-fluoro-anilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]benzamide) is a compound represented by the following formula (2). Compound 2 is used, for example, as a sodium salt. [ka]
[0055] CH4987655 (CAS number: 874101-00-5, 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(tetrahydro-3-oxo-2H-1,2-oxazin-2-yl)methyl]benzamide, RO4987655) is a compound represented by the following formula (15). [ka]
[0056] Selumetinib (CAS number: 606143-52-6, 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide) is a compound represented by the following formula (16). Selumetinib is used as selumetinib sulfate or KOSELUGO. [ka]
[0057] Sorafenib (CAS number: 284461-73-0, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide, a compound represented by the following formula (17). Sorafenib is used as sorafenib tosylate or Nexavar. [ka]
[0058] Pazopanib (CAS number: 444731-52-6, 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide, a compound represented by the following formula (18). Pazopanib is used as pazopanib hydrochloride or Votrient. [ka]
[0059] Sunitinib (CAS number: 557795-19-4, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) is a compound represented by the following formula (19). Sunitinib is used as sunitinib malate or sutent. [ka]
[0060] Axitinib (CAS number: 319460-85-0, N-methyl-2-[[3-[(E)-2-(2-pyridyl)vinyl]-1H-indazol-6-yl]sulfanyl]benzamide is a compound represented by the following formula (20). Axitinib is used as an inlighter. [ka]
[0061] Regorafenib (CAS number: 755037-03-7, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluoro-phenoxy]-N-methyl-pyridine-2-carboxamide, a compound represented by the following formula (21). Regorafenib is used as regorafenib hydrate or Stivarga. [ka]
[0062] The dosage of the molecular targeted agent is preferably 0.005-100 mg / kg / day per kg of the subject's body weight, more preferably 0.01-75 mg / kg / day, even more preferably 0.02-50 mg / kg / day, and most preferably 5-40 mg / kg / day. When the dosage of the molecular targeted agent is within these ranges, the cancer treatment or prevention effect is further enhanced. The frequency of administration of the molecular targeted agent can be, for example, once or more per week, or twice per week. The same dosage and / or method of administration can be applied to compound 1 or a salt thereof, or a solvate thereof.
[0063] The dosage of compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent is preferably 0.001 to 100 mg / kg / day of compound 1 or a salt thereof or a solvate thereof and 0.005 to 100 mg / kg / day of the molecular targeted agent per 1 kg of the body weight of the subject to be administered, more preferably 0.003 to 20 mg / kg / day of compound 1 or a salt thereof or a solvate thereof and 0.01 to 75 mg / kg / day of the molecular targeted agent, and even more preferably 0.003 to 10 mg / kg / day of compound 1 or a salt thereof or a solvate thereof and 0.02 to 30 mg / kg / day of the molecular targeted agent. When the dosage of compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent is within these ranges, the therapeutic or preventive effect of cancer is further enhanced. The dosage and method of administration can be appropriately adjusted while observing the blood drug concentration such as AUC and Cmax and the condition of the patient. For the appropriate dosage and number of administrations (administration frequency), for example, the package insert of the molecular targeted drug can be referred to. The method of administration of Compound 1 or a salt thereof, or a solvate thereof may be, for example, once or more times a day, or may be twice a day. The method of administration of Compound 1 or a salt thereof, or a solvate thereof is preferably once a day.
[0064] In the present invention, the administration method includes oral, rectal, parenteral (intravenous, intramuscular, subcutaneous, transdermal), intracisternal, intravaginal, intraperitoneal, intravesical, or local (injection, drip, powder, ointment, gel, or cream) administration and inhalation (intraoral or nasal spray). The administration form includes, for example, tablets, capsules, granules, powders, pills, aqueous and non-aqueous oral solutions and suspensions, and parenteral solutions filled in containers adapted for subdivision into individual doses. The administration form can also be adapted to various administration methods, including controlled release formulations such as subcutaneous implants. The administration method is equally applicable to the first active ingredient and the second active ingredient. The first active ingredient and the second active ingredient can be used as pharmaceuticals and can be administered as formulations or combinations.
[0065] The first active ingredient may be administered by any of the above-mentioned administration methods, and the second active ingredient may be administered by the same or different administration method as the first active ingredient. The interval between the administration of the first active ingredient and the second active ingredient may be, for example, 0 to 14 days, 0 to 10 days, or 0 to 7 days. The interval between the administrations may be determined, for example, by using the AUC, Cmax, Tmax, elimination half-life, or the health condition of the subject as an index. For example, compound 1 or a salt thereof or a solvate thereof may be administered orally (tablets, capsules, etc.), and the molecular targeted agent may be administered by infusion. For example, compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent may both be administered orally (tablets, capsules, etc.). For example, compound 1 or a salt thereof or a solvate thereof may be administered by infusion, and the molecular targeted agent may both be administered orally (tablets, capsules, etc.). For example, compound 1 or a salt thereof or a solvate thereof may be administered by infusion, and the molecular targeted agent may both be administered orally (tablets, capsules, etc.). For example, compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent may both be administered by infusion. In such a case, compound 1 or its salt or solvate thereof and the molecular targeted agent may be administered at any interval, such as twice a day, once a day, once a week, or once every two weeks. More specifically, compound 1 or its salt or solvate thereof and the molecular targeted agent may be administered once a day, and in this case, may be administered before, between, or after a meal. Before, between, or after a meal may be before, between, or after breakfast, lunch, dinner, midnight snack, or snack. If the administration interval between compound 1 or its salt or solvate thereof and the molecular targeted agent is within 24 hours, both may be administered once a day. Depending on the need, compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent may be administered twice a day and once a day, once a day and once a day, once a day and twice a day, once a day and once every two days, once a day and once every three days, once a day and once every seven days, and twice a day and once every seven days, respectively.If necessary, based on the AUC, Cmax, Tmax or elimination half-life of compound 1 and / or the molecular targeted agent, or the health condition of the patient, only the administration interval of the molecular targeted agent can be increased or decreased, or only the administration interval of compound 1 or a salt thereof or a solvate thereof can be increased or decreased. The administration of the molecular targeted agent may be started on the start date of administration of compound 1 or a salt thereof or a solvate thereof, or the start date of administration of compound 1 or a salt thereof or a solvate thereof may be different from the start date of administration of the molecular targeted agent. The administration period is 7 days per course, and the total number of courses can be one course or more, or can be two courses or more. In addition, each course may be performed consecutively, or a drug holiday may be provided. A drug holiday may be provided in the middle of a course. If necessary, only compound 1 or a salt thereof or a solvate thereof may be continuously administered during the course and the molecular targeted agent may be suspended, or only compound 1 or a salt thereof or a solvate thereof may be suspended and the molecular targeted agent may be continuously administered. Compound 1 or a salt thereof or a solvate thereof and the molecular targeted agent may be contained in the same tablet, capsule, etc.
[0066] The pharmaceutical preparation of the present invention can be formulated by a known method by introducing a pharma- ceutical acceptable carrier in addition to an active ingredient such as Compound 1 or a salt thereof, or a solvate thereof or a molecular targeting agent. For formulation, commonly used excipients, binders, lubricants, colorants, flavorings, and stabilizers, emulsifiers, absorption promoters, surfactants, pH adjusters, preservatives, antioxidants, etc. can be used, and ingredients generally used as raw materials for pharmaceutical preparations can be mixed and formulated by a conventional method. In the formulation, the active ingredient used in the pharmaceutical product can be processed into an optimal shape and properties, i.e., dosage form, according to the method of use and purpose of use, by a known method. Commonly used dosage forms include liquid pharmaceutical preparations (liquids) such as injections, suspensions, emulsions, and eye drops, and solid pharmaceutical preparations (solid preparations) such as tablets, powders, fine granules, granules, coated tablets, capsules, dry syrups, lozenges, and suppositories, but are not limited to these. For example, a preparation containing an active ingredient such as Compound 1 or a salt thereof, or a solvate thereof, or a molecular targeted agent can be used as the medicament of the present invention.
[0067] The therapeutic or preventive medicine of the present invention may be used by mixing either or both of the first and second active ingredients with a medicament that is acceptable as a pharmaceutical. The medicament that is acceptable as a pharmaceutical may be appropriately selected from additives well known to those skilled in the art, and multiple additives may be appropriately used as necessary. The additive is appropriately selected depending on the oral agent or injection, and may be mixed with, for example, water, ethanol, physiological saline, liquid paraffin, surfactant, sucrose, etc., and the resulting mixture may be encapsulated.
[0068] Cancers include solid cancers and blood cancers, both of which are composed of abnormal cells that grow uncontrollably. Solid cancers form one or many tumors, while blood cancers circulate throughout the body via the bloodstream. The cancer may be, for example, at least one selected from the group consisting of lung cancer, esophageal cancer, stomach cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma. The cancer may be cancer associated with an abnormality in the RAS gene. Preferably, the cancer is lung cancer, pancreatic cancer, or colon cancer.
[0069] As used herein, "abnormality" refers to a state in which various chromosomes, genes, proteins, and signal transduction cascades within a cell deviate from their normal functions and controls, and is usually triggered by the constitutive activation of these.
[0070] As used herein, "abnormal activation" refers to a state in which various chromosomes, genes, proteins, and signal cascades in a cell are more activated than in normal cells, and may be caused, for example, by genetic mutations (Cancer Metastasis Rev, 2013, 32, 147-162). To directly and quantitatively measure the involvement of mutants in cells, cell activation can be measured, for example, by LC / MS-MS-based assays (Cancer Discov., 2016, 6, 316-329).
[0071] "Protein amplification" refers to the synthesis and amplification of proteins in living cells, such as the amplification of proteins involved in the MAPK / ERK pathway (e.g., KRAS, NRAS, HRAS, KRAS-GTP, NRAS-GTP, HRAS-GTP, ERK, AKT, MEK, pERK, pAKT, pMEK). Protein amplification can be confirmed by measuring the protein by Western blotting or comparative genomic hybridization (CGH), etc., and comparing it with the protein in normal cells (Nat.Rev.Drug Discov., 2020, 19,533-552, Molecular Cytogenetics, 2015, 8:103).
[0072] In one aspect, cancer includes cancer associated with abnormality of RAS gene. Cancer associated with abnormality of RAS gene refers to, for example, cancer in which cancer cells have mutation in coding region of RAS gene and / or amplification of copy number of RAS gene, and increase in RAS activity (including increase in production of RAS protein) is observed. Mutation in coding region of RAS gene refers to, for example, deletion, addition or substitution of one or more bases in coding region of RAS gene. Amplification of copy number of RAS gene refers to the presence of more copies of RAS gene than the copy number of RAS gene normally present on chromosome. A large copy number means more than normal cells, and if the copy number is 4 or more, it can be said that the copy number is amplified.
[0073] Whether a cancer is associated with an abnormality in the RAS gene can be determined by confirming whether a subject with cancer has an abnormality in the RAS gene. For example, by identifying a mutation in the base sequence of the coding region of the RAS gene in a biological sample obtained from a subject with cancer and further confirming the expression of a mutated RAS protein, it can be determined that the cancer is associated with an abnormality in the RAS gene.
[0074] Whether a cancer is related to the abnormality of the RAS gene can be determined by checking whether a subject suffering from cancer has an amplification of the copy number of the RAS gene. For example, by checking whether the copy number of the RAS gene is amplified and / or the production of RAS protein is increased in a biological sample obtained from a subject suffering from cancer, it can be determined that the cancer is related to the abnormality of the RAS gene. The increase in the production of RAS protein can also be called overexpression of RAS protein. Whether the production of RAS protein is increased can be determined by, for example, comparing the expression level of a general RAS protein, the expression level of a RAS protein in a subject not suffering from the cancer, or the expression level of a RAS protein in a subject before suffering from the cancer.
[0075] When a subject suffering from cancer has a mutation in the base sequence of the coding region of the RAS gene and the copy number of the RAS gene is amplified, the cancer can also be said to be associated with an abnormality in the RAS gene.
[0076] Any method can be used as long as it can detect the mutation in the coding region of RAS gene or the amplification of the copy number of RAS gene in the biological sample of a subject suffering from cancer, and can be performed by a person skilled in the art in a conventional manner.For example, RAS gene can be isolated from a biological sample obtained from a subject suffering from cancer, amplified by PCR or the like, and its base sequence can be directly determined by a sequencer or the like.Otherwise, for example, a commercially available in vitro diagnostic agent that can detect the mutation of RAS gene can be used.
[0077] As the isoforms of RAS protein, there are three known types: KRAS protein, NRAS protein, and HRAS protein.In one aspect, RAS gene is one or more RAS genes selected from the group consisting of KRAS gene, NRAS gene, and HRAS gene.Preferably, RAS gene is KRAS gene.
[0078] In one aspect, the cancer includes cancers associated with the production of mutant RAS proteins and / or increased production of RAS proteins, which usually result from abnormalities in the RAS genes described above.
[0079] In one aspect, the mutant RAS protein is at least one mutant RAS protein selected from the group consisting of mutant KRAS protein, mutant NRAS protein, and mutant HRAS protein.Preferably, the mutant RAS protein is mutant KRAS protein.
[0080] In one aspect, the mutant RAS protein has a mutation at at least one amino acid position selected from the group consisting of G12, G13, and Q61 in the amino acid sequence of a human wild-type KRAS protein, a human wild-type NRAS protein, or a human wild-type HRAS protein. In the amino acid sequences of the human wild-type KRAS protein, NRAS protein, and HRAS protein, the 12th and 13th amino acids are glycine, and the 61st amino acid is glutamine.
[0081] In one aspect, the mutant RAS protein is a mutant KRAS protein and has at least one amino acid mutation selected from the group consisting of G12A, G12C, G12D, G12S, G12V, G13D, Q61H, and Q61K compared to the amino acid sequence of wild-type KRAS.
[0082] In one aspect, the mutant RAS protein is a mutant NRAS protein and has at least one amino acid mutation selected from the group consisting of G12C, G12D, G13D, G13V, Q61K, and Q61L compared to the amino acid sequence of wild-type NRAS.
[0083] In one aspect, the mutant RAS protein is a mutant HRAS protein and has an amino acid mutation of G13R compared to the amino acid sequence of wild-type HRAS. EXAMPLES
[0084] The present invention will be further described in the following examples, but the present invention is not limited thereto. All compounds and reagents are obtained from commercial suppliers or synthesized using known methods. In the present examples, molecular targeting agents may be referred to as combination compounds.
[0085] Compound 1 ((5S,8S,11S,15S,18S,23aS,29S,35S,37aS)-8-((S)-sec-butyl)-18-cyclopentyl-29-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-36-ethyl-11-isobutyl-N,N,5,6,12,16,19,33-octamethyl-35-(4-methylbenzyl)-4,7,10,13,17,20,23,28, 31,34,37-Undecaoxotetratriacontahydro-2H,4H-spiro[azeto[2,1-u]pyrrolo[2,1-i][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotetratriacontin-21,1'-cyclopentane]-15-carboxamide) was prepared according to the peptide synthesis method using the Fmoc method described in WO 2021 / 090855. That is, 1) The carboxyl group of (3S)-4-(dimethylamino)-3-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-oxo-butanoic acid is supported on 2-chlorotrityl resin, and a peptide elongation reaction is performed from the N-terminus of the amino acid by the Fmoc method according to the sequence of compound 1. 2) Cleavage reaction of peptides from 2-chlorotrityl resin It was produced in four steps: 3) an amide cyclization reaction by condensation of the carboxyl group released from the 2-chlorotrityl resin by the cleavage reaction with the amino group at the N-terminus of the peptide chain (N-methylleucine); and 4) purification of the compound by preparative HPLC.
[0086] Compound 2 (2-(4-cyclopropyl-2-fluoro-anilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)-4-pyridyl]methyl]benzamide) was prepared according to the method described in WO 2021 / 149776. That is, 1) 2,3,4-trifluorobenzoic acid, available from a commercial supplier, was reacted with iodine to give 2,3,4-trifluoro-5 iodo-benzoic acid. 2) The compound obtained in the above reaction was subjected to a coupling reaction with potassium vinyltrifluoroborate in the presence of a palladium catalyst to obtain 2,3,4-trifluoro-5-vinyl-benzoic acid. 3) The compound obtained in the above reaction was subjected to a coupling reaction with 2-fluoro-4-iodo-aniline to obtain 3,4-difluoro-2-(2-fluoro-4-iodo-anilino)-5-vinyl-benzoic acid. 4) The compound obtained in the above reaction was treated with sodium periodate and osmium tetroxide to obtain 3,4-difluoro-2-(2-fluoro-4-iodo-anilino)-5-formyl-benzoic acid. 5) The compound obtained in the above reaction was reacted with a diazomethyltrimethylsilane hexane solution in methanol to obtain methyl 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-formylbenzoate. 6) The compound obtained in the above reaction was reacted with 4-methylbenzenesulfonyl hydrazide to obtain methyl 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-5-[(E)-[(4-methylphenyl)sulfonylhydrazinylidene]methyl]benzoate. 7) The compound obtained in the above reaction was reacted with [2-[(2,4-dimethoxyphenyl)methylamino]-3-fluoropyridin-4-yl]boronic acid to obtain methyl 5-[[2-[(2,4-dimethoxyphenyl)methylamino]-3-fluoropyridin-4-yl]methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoate. 8) The compound obtained in the above reaction was reacted with trifluoroacetic acid to obtain methyl 5-[(2-amino-3-fluoropyridin-4-yl)methyl]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoate. 9) The compound obtained in the above reaction was hydrolyzed with lithium hydroxide to remove the ester group, and then treated with hydrochloric acid to obtain 5-((2-amino-3-fluoropyridin-4-yl)methyl)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid hydrochloride. 10) The compound obtained in the above reaction was treated with EDC·HCl, HOOBt, and ammonia in methanol to give 5-((2-amino-3-fluoropyridin-4-yl)methyl)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide. Then, cyclopropylzinc bromide was added to give 5-((2-amino-3-fluoropyridin-4-yl)methyl)-2-((4-cyclopropyl-2-fluorophenyl)amino)-3,4-difluorobenzamide. 11) The compound obtained in the above reaction (2.47 g, 5.74 mmol) was dissolved in anhydrous DMF (28.7 mL), pyridine (2.78 mL, 34.4 mmol) and 4-nitrophenyl methylsulfamate (4.00 g, 17.2 mmol) were added, and the mixture was stirred at 40° C. for 2.5 hours. The reaction mixture was cooled to room temperature, and water (24.7 mL) was added. Acetonitrile (3 mL) and water (19.8 mL) were added, and the mixture was stirred for 10 minutes, after which the solid was filtered off. The solid obtained was washed with water / acetonitrile (1 / 1, 49.4 mL) to obtain compound 2 (2.56 g, 85%) as a colorless solid. Molecular targeted agents other than compound 2 (sotrasib, RMC-4550, trametinib, and cetuximab) were supplied by commercial suppliers or manufacturers.
[0087] <Pharmacological test examples> Example 1: In vitro evaluation of RAS signal inhibitory activity The effects of compound 1, compound 2, RMC-4550, trametinib, sotorasib, and the combination of these compounds on the phosphorylation of ERK, AKT, and MEK in human cancer cells, and on the binding of KRAS, NRAS, and HRAS to GTP were examined by Western blotting as follows. Human cancer cell lines were seeded on a 3D culture plate PrimeSurface (Sumitomo Bakelite) and cultured at 37°C for 24 hours. Compound 1 and the combination compound (molecular targeting agent) were then added to the cells. The cells were cultured at 37°C in a 5% carbon dioxide incubator, and the cells were harvested after the treatment time shown in Table 1 had elapsed. The human cancer cell line name, medium, cell seeding number, compound 1 concentration, combination compound, combination compound concentration, and treatment time are shown in Table 1. The harvested cells were lysed in lysis buffer (Cell Signaling Technology) containing protease inhibitors (Sigma-Aldrich) and phosphatase inhibitors (Sigma-Aldrich). Protein concentration was measured using a BCA protein assay kit (ThermoFisher Scientific), and protein solution 1 was adjusted to 10 to 20 μg per sample.
[0088] From 300-1000μg of the obtained protein solution 1, the activated form RAS-GTP was collected using the Active Ras Pull-Down and Detection Kit (ThermoFisher Scientific) to prepare protein solution 2. SDS-PAGE was performed using the above protein solutions 1 and 2 and a gradient gel with an acrylamide concentration of 5-20%, and the electrophoresed proteins were transferred to a PVDF membrane using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories). After blocking, the PVDF membrane was reacted with the primary antibody and the secondary antibody in this order. Chemiluminescence was generated using Chemi-lumi One Super (Nacalai Tesque), and bands were detected using the ChemiDoc Touch Imaging System (Bio-Rad Laboratories). The primary antibody, secondary antibody, dilution concentration of each antibody, reaction temperature, and reaction time used are shown in Tables 2 and 3. The electrophoretic images showing the results of Western blotting for evaluating RAS signal inhibitory activity are shown in Figures 1 to 6. "pERK", "pAKT" and "pMEK" represent phosphorylated ERK, AKT and MEK, respectively. "KRAS-GTP", "NRAS-GTP" and "HRAS-GTP" represent KRAS, NRAS and HRAS bound to GTP, respectively. Figures 1 to 6 show that the inhibitory effect of RAS signaling was enhanced when compound 1 and a combined compound (molecular targeted agent) were used in combination, compared with when compound 1 or a combined compound (molecular targeted agent) was used alone.
[0089] [Table 1]
[0090] [Table 2]
[0091] [Table 3]
[0092] (Example 2 Evaluation of Cell Growth Inhibitory Activity by Compound 1 and Combinatorial Compounds (Molecular Targeting Agents)) A human cancer cell line was seeded at a concentration of 750 cells per well on an ultra-low attachment surface U-bottom 384-well plate and cultured in a 37 °C, 5% carbon dioxide incubator. After 24 hours, CellTitorGlo 2.0 (Promega) was added to a part of the wells (3 wells), and the amount of ATP (V0) was measured using an Envision plate reader (Perkin Elmer). V0 was taken as the amount of ATP at the 0-hour time point. DMSO alone, or Compound 1 and / or combinatorial compounds were added to separate sets of 3 wells each. Compound 1 was serially diluted in 8 steps with a common ratio of 3 with a maximum concentration of 300 nM, and the combinatorial compounds were serially diluted in 8 steps with a common ratio of 3 with maximum concentrations of 10 or 3000 nM. In Table 4, for example, "0.14~300" means the case where the maximum concentration is "300" nM, indicating that dilution solutions of "300, approximately 100, approximately 33, approximately 11, approximately 3.7, approximately 1.2, approximately 0.41 or approximately 0.14 nM" were used. After culturing for 144 hours after adding DMSO alone, or Compound 1 and / or combinatorial compounds, the amount of ATP (T and V) of the cells to which only DMSO was added (DMSO treatment group), or the cells to which Compound 1 and / or combinatorial compounds were added (Compound 1 and / or combinatorial compound treatment group) was measured respectively. The names of the cancer cell lines, the medium, the concentration of Compound 1, the combinatorial compounds, and the concentrations of the combinatorial compounds are shown in Table 4. The growth inhibition rate (GI%: Growth Inhibition%) was calculated using the following formula. As shown in FIGS. 7a, 8a and 9a, a concentration-dependent growth inhibitory effect of Compound 1 and the combinatorial compounds was shown. (1-(T-V0) / V0)×100 (when T<V0) (1-(T-V0) / (V-V0))×100 (when T≧V0) T: ATP signal value at the 144-hour time point of the Compound 1 and / or combinatorial compound treatment group V: ATP signal value at the 144-hour time point of the DMSO treatment group V0: ATP signal value of the untreated group
[0093] Using the obtained GI values, an analysis based on the isobologram method was carried out according to the following procedure. The following GI values were used in evaluating the combined effect. (1) Calculation of GI% (set GI%) for evaluating the combined effect of Compound 1 and a combined compound, and the compound concentration (set GI concentration) that gives the set GI% Combination study of Compound 1 and RMC-4550 (NCI-H358): The set GI% was 155% (sometimes referred to as "GI155%" or "GI155"). (The set GI concentration of Compound 1 was 0.033 μM, and the set GI concentration of RMC-4550 was 0.55 μM.) Combination study of Compound 1 and RMC-4550 (NCI-H441): The set GI% was 100% (sometimes referred to as "GI100%" or "GI100"). (The set GI concentration of Compound 1 was 0.0055 μM, and the set GI concentration of RMC-4550 was 0.35 μM.) Combination study of Compound 1 and trametinib (NCI-H358): The set GI% was 50% (sometimes referred to as "GI50%" or "GI50"). (The set GI concentration of Compound 1 was 0.0046 μM, and the set GI concentration of trametinib was 0.00035 μM.) (2) Examination of combinations of concentrations of compound 1 and the concomitant compounds that give each set GI% in (1) and visualization of the combined effect in a graph The horizontal axis represents the value obtained by dividing the concentration of the combined compound by the set GI concentration, and the vertical axis represents the value obtained by dividing the concentration of compound 1 by the set GI concentration. The concentrations of compound 1 and the combination of compounds that gave the set GI% in various cell lines were measured and plotted on a graph according to the values on the horizontal and vertical axes.
[0094] The results of the cell growth inhibitory activity evaluation of compound 1 and the combined compound are shown in Figures 7 to 9. Each of Figures 7b, 8b, and 9b is a graph called an isobologram. The dashed line connecting "1.0" on the vertical axis of the isobologram to "1.0" on the horizontal axis indicates the case where the growth inhibitory effect when compound 1 is used in combination with the combined compound is a simple sum of the growth inhibitory effects when each compound is used alone (when the effect is additive). A plot below the dashed line means that a synergistic growth inhibitory effect was observed when compound 1 was used in combination with the combined compound. The further the plot is from the dashed line, the stronger the synergistic effect is. As shown in Figures 7b, 8b, and 9b, the plots are farther from the dashed line in each figure, so it was found that the combined use of compound 1 and the combined compound exhibited a synergistic growth inhibitory effect.
[0095] [Table 4]
[0096] Example 3: Evaluation of in vivo antitumor activity by combined use of Compound 1 and cetuximab The in vivo antitumor activity of the combination of compound 1 and cetuximab was evaluated using a xenograft model in which colon cancer cell line LoVo (KRAS-G13D) was transplanted. Nude mice were subcutaneously injected with 5 × 10 6 Cells were transplanted and the tumor volume was 200-300 mm 3When the number of mice reached 100, the nude mice were randomized and divided into 4 groups of 8 mice each. Compound 1 or cetuximab was administered to the single-drug administration group (8 mice per group), and compound 1 and cetuximab were administered to the double-drug administration group (8 mice per group). The administration period was 10 days, and compound 1 was administered orally once a day, and cetuximab was administered intravenously twice a week. Compound 1 was administered at 10 mg / kg per administration, and cetuximab was administered at 40 mg / kg per administration. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% Distilled water and administered. Cetuximab was diluted with saline and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula. The results of the in vivo antitumor activity evaluation are shown in Figure 10. Compared to the vehicle group, the drug administration groups (compound 1 monotherapy group, cetuximab monotherapy group, and compound 1 and cetuximab dual therapy group) showed suppressed increase in tumor volume. Furthermore, when comparing the monotherapy group with the dual therapy group (combination group), the tumor volume was reduced in the dual therapy group, indicating the enhanced in vivo antitumor activity of the combination of compound 1 and cetuximab. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = tumor volume on Day 32, 36 or 39 - tumor volume on Day 29 TV: Mean tumor volume change in the compound 1 monotherapy group, the cetuximab monotherapy group, and the combination therapy group CV: Mean tumor volume change in the vehicle group
[0097] Example 4: In vivo evaluation of RAS signal inhibitory activity After the end of Example 3, compound 1 (10 mg / kg) and cetuximab (40 mg / kg) were re-administered to nude mice (n=3), and the tumors were collected 4 hours later, frozen in liquid nitrogen, and stored at -80°C. The collected tumors were then crushed with a multi-beads shocker (Yasui Kikai) under cooling with liquid nitrogen, and the RAS signal inhibitory activity of compound 1 and cetuximab in the xenograft model was evaluated based on the same protocol as in Example 1 (in vitro RAS signal inhibitory activity evaluation). The primary and secondary antibodies used, the dilution concentrations of each antibody, the reaction time, and the reaction temperature are shown in Tables 5 and 6. The electrophoretic images showing the results of Western blotting for the in vivo RAS signal inhibitory activity evaluation are shown in Figure 11. "KRAS-GTP" represents "KRAS" bound to GTP, and "pERK", "pAKT" and "pEGFR" represent phosphorylated "ERK", "AKT" and "EGFR", respectively. Compared with the use of compound 1 or cetuximab alone, the combined use of compound 1 and cetuximab showed a decrease in KRAS-GTP and pERK, indicating enhanced inhibition of RAS signaling.
[0098] [Table 5]
[0099] [Table 6]
[0100] Example 5: Evaluation of in vivo antitumor activity by combination of Compound 1 and bevacizumab The in vivo antitumor activity of the combination of compound 1 and bevacizumab was evaluated using a xenograft model in which pancreatic cancer line AsPC-1 (KRAS-G12D) was transplanted. Nude mice were subcutaneously injected with 5 × 10 6 The number of cells was transplanted, and the tumor volume was 200–300 mm 3When the number of mice reached 100, the nude mice were randomized and divided into 4 groups of 8 mice each. Compound 1 or bevacizumab was administered to the single-drug administration group (8 mice per group), and compound 1 and bevacizumab were administered to the double-drug administration group (8 mice per group). The administration period was 17 days, and compound 1 was administered orally once a day, and bevacizumab was administered by intraperitoneal injection twice a week. Compound 1 was administered at 10 mg / kg per administration, and bevacizumab was administered at 2.5 mg / kg per administration. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% Distilled water and administered. Bevacizumab was diluted with saline and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula. The results of the in vivo antitumor activity evaluation are shown in Figure 12. Compared to the vehicle group, the increase in tumor volume was suppressed in the compound 1 monotherapy group and the compound 1 and bevacizumab dual therapy group. On the other hand, no significant suppression of tumor volume increase was observed in the bevacizumab monotherapy group. Furthermore, in a comparison between the monotherapy group and the dual therapy group (combination group), the tumor volume was reduced in the dual therapy group, indicating the enhanced in vivo antitumor activity of the combination of compound 1 and bevacizumab. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = Tumor volume after Day 25, 29, 32, 36, or 39 - Tumor volume on Day 22 TV: Mean change in tumor volume in the compound 1 group, bevacizumab group, or combination group CV: Mean tumor volume change in the vehicle group
[0101] Example 6: Evaluation of cell proliferation inhibitory activity by combined use of compound 1 and sotorasib Human colon cancer cell line SW837 was seeded at 10,000 cells per well (n=3) in a 96-well 2D culture plate (Corning) and cultured at 37°C in a 5% carbon dioxide incubator. The medium used was Leibovitz's L-15 + 10% serum. 24 hours after seeding, the medium was replaced with a medium containing DMSO / compound 1 30nM / sotorasib 300nM / compound 1 30nM + sotorasib 300nM, and cell density measurements were started every 24 hours using an Icucyte ZOOM. The medium was replaced with a medium containing the compound about twice a week, and measurements were performed for 52 days. The cell proliferation inhibitory activity of the combined use of compound 1 and sotorasib is shown in Figure 13. In Fig. 13, the vertical axis represents the percentage of the culture vessel adhesion surface covered by cultured cells (cell density, cell occupancy rate, confluency), and the horizontal axis represents the number of days elapsed since the start of cell density measurement. As shown in Fig. 13, the combined use of compound 1 and sotorasib enhanced the growth inhibitory effect on the human colon cancer cell line SW837.
[0102] Example 7: Evaluation of cell proliferation inhibitory activity of Compound 1 and a combination compound Human cancer cell lines were seeded on low-adsorption surface U-bottom 384 plates (Sumitomo Bakelite) at 1000 cells (HCC-1171), 500 cells (NCI-H1373), 625 cells (NCI-H23), and 250 cells (UM-UC-3) per well (n=1), and cultured in a 37°C, 5% carbon dioxide incubator. The media containing compound 1 and / or the combined compounds were prepared so that when compound 1 and MRTX849 were used in combination, compound 1 was serially diluted in 9 steps with a common ratio of 3, and MRTX849 was serially diluted in 5 steps with a common ratio of 5. When compound 1 and TNO155 were used in combination, compound 1 was serially diluted in 9 steps with a common ratio of 3, and TNO155 was serially diluted in 5 steps with a common ratio of 5. The combination effect was verified by mixing all combinations of the set concentrations of the two drugs (10 concentrations and 6 concentrations, including the DMSO group). After 144 hours of culture after addition of Compound 1 and / or the combined compound, the amount of ATP in the compound-treated group was measured using CellTitorGlo2.0. The cancer cell line name, medium, compound name, and final test concentration of the compound are shown in Table 7. The cell growth inhibition rate (CGI%: Cell Growth Inhibition%) was calculated from the signal value obtained by CellTitorGlo2.0 using the following formula. Cytostatic rate (CGI%) = (1-(TV-V0) / (CV-V0)) x 100 TV: ATP signal value at 144 hours in the compound-treated group CV: ATP signal value at 144 hours in the DMSO-treated group V0: ATP signal value at 144 hours with medium alone (no cells seeded)
[0103] Using the obtained CGI values, analysis based on the isobologram method was performed according to the following procedure. The results of the cell proliferation inhibitory activity evaluation by compound 1 and the combined compound are shown in Figures 14 and 15. The X-axis (horizontal axis) and Y-axis (vertical axis) are the concentrations of compound 1 and the combined compound, respectively. First, the concentrations of compound 1 alone and the combined compound alone required to exert the CGI 50% value (HCC-1171, NCI-H1373, NCI-H23) or CGI 70% value (UM-UC-3) were plotted on the X-axis or Y-axis. The straight line connecting the plot on the X-axis and the plot on the Y-axis indicates the case where the proliferation inhibitory effect when compound 1 and the combined compound are used in combination is a simple sum of the proliferation inhibitory effect when each compound is used alone (the effect is additive). Next, the concentrations of compound 1 and the combined compound required to exert the CGI value when the drugs are used in combination were plotted. When the plot of the combined use is located at the bottom of the line connecting the plot on the X axis and the plot on the Y axis, it means that the combination of drugs showed a synergistic growth inhibitory effect, and the further the plot is from the line, the stronger the synergistic effect. As shown in Figures 14 and 15, the plots in each figure are far from the line, so it was found that the combined use of Compound 1 and the combined compound showed a synergistic growth inhibitory effect.
[0104] [Table 7]
[0105] Example 8: Evaluation of in vivo antitumor activity by combined use of Compound 1 and sotorasib The in vivo antitumor activity of the combination of compound 1 and sotorasib was evaluated using nude mice implanted with CTG-2579 (KRAS-G12C), a lung cancer PDX (patient-derived xenograft) model. Tumor fragments were implanted subcutaneously into nude mice, and tumor volumes of approximately 150–300 mm were examined. 3When the tumor volume reached 100 mg / kg, randomization was performed and administration of compound 1 and / or the combined compound was started (n=8). Compound 1 and sotorasib were orally administered once a day for 21 days. The drug dose was 7.5 mg / kg for compound 1 and 100 mg / kg for sotorasib. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% distilled water, and sotorasib was dissolved in 10% DMSO / 10% Cremphor EL / 15% PEG400 / 2.64% HPBCD / 62.36% distilled water and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula from the tumor volume data on the final measurement day. The results of the in vivo antitumor activity evaluation are shown in Figure 16. Compared to the vehicle group, the compound 1 single agent administration group, the sotorasib single agent administration group, and the compound 1 and sotorasib dual agent administration group showed suppressed increase in tumor volume. Furthermore, in comparison between the single agent administration group and the dual agent administration group (combination group), the tumor volume was reduced in the dual agent administration group, indicating the enhanced in vivo antitumor activity of the combination of compound 1 and sotorasib. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 0.52 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = Tumor volume after Day 0 - Tumor volume on Day 0 TV: Mean change in tumor volume in the compound 1 group, the sotorasib group, or the combination group CV: Mean tumor volume change in the vehicle group
[0106] Example 9: Evaluation of in vivo RAS signal inhibitory activity by combined use of compound 1 and sotorasib After the end of Example 8, compound 1 and sotorasib were re-administered to nude mice (n=3) at 7.5 mg / kg and 100 mg / kg, respectively, and the tumors were collected 4 hours later, frozen in liquid nitrogen, and stored at -80°C. The collected tumors (PDX samples) were then crushed with a multi-beads shocker (Yasui Kikai) under cooling with liquid nitrogen, and the RAS signal inhibitory activity of compound 1 and sotorasib in PDX was evaluated based on the same protocol as in the in vitro RAS signal inhibitory activity evaluation of Example 1. The primary antibody, secondary antibody, dilution concentration, reaction time, and reaction temperature used are shown in Tables 8 and 9. The results of the electrophoretic image showing the results of Western blotting for the in vivo RAS signal inhibitory activity evaluation are shown in Figure 17. "KRAS-GTP" represents "KRAS" bound to GTP, and "pERK" and "pAKT" represent phosphorylated "ERK" and "AKT", respectively. It was shown that the combination of compound 1 and sotorasib reduced pERK and enhanced the inhibition of MAPK signaling compared with the single use of compound 1 or sotorasib.
[0107] [Table 8]
[0108] [Table 9]
[0109] Example 10: Evaluation of in vivo antitumor activity by combined use of Compound 1 and MRTX849 The in vivo antitumor activity of the combination of compound 1 and MRTX849 was evaluated using xenograft models implanted with lung cancer line LU65 (KRAS-G12C) or bladder cancer line UM-UC-3 (KRAS-G12C). Nude mice were subcutaneously implanted with 5 × 10 6 Cells were transplanted and the tumor volume was 200-300 mm 3When the tumor volume reached 100 μg / kg, the nude mice were randomized and administration of compound 1 and / or the combined compound was started (n=6). Compound 1 and MRTX849 were orally administered once a day for a period of 45 days. The drug dose was 3 mg / kg for compound 1 and 100 mg / kg for MRTX849. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% Distilled water, and MRTX849 was dissolved in 50 mM Citrate buffer (pH 5.0) / 10% HPBCD and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula from the tumor volume data on the final measurement day. The results of the in vivo antitumor activity evaluation are shown in Figure 18. In lung cancer model (LU65) and bladder cancer line model (UM-UC-3), the increase in tumor volume was suppressed in the MRTX849 single agent administration group and the group administered both compound 1 and MRTX849, compared to the vehicle group. The group administered both compound 1 did not show any inhibition of the increase in tumor volume. In the MRTX849 single agent administration group, the increase in tumor volume was suppressed immediately after the start of administration, but tumor regrowth was observed in multiple mice as administration continued. The group administered both drugs (combination group) showed a long-term inhibition of tumor regrowth observed in the MRTX849 single agent group, indicating the enhanced in vivo antitumor activity of the combination of compound 1 and MRTX849. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = Tumor volume after Day 0 - Tumor volume on Day 0 TV: Mean change in tumor volume in the compound 1 group, MRTX849 group, or combination group CV: Mean tumor volume change in the vehicle group
[0110] Example 11: Evaluation of in vivo antitumor activity by combined use of Compound 1 and TNO155 The in vivo antitumor activity of the combination of compound 1 and TNO155 was evaluated using a xenograft model implanted with the lung cancer line NCI-H1373 (KRAS-G12C). Nude mice were subcutaneously injected with 5 × 10 6 The cells were transplanted and the tumor volume was 200-300 mm 3 When the tumor volume reached 100 μg / kg, the nude mice were randomized and administration of compound 1 and / or the combined compound was started (n=8). Compound 1 was orally administered once a day, and TNO155 was orally administered twice a day for a period of 35 days. The drug dose was 5 mg / kg for compound 1 and 5 mg / kg for TNO155. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% Distilled water, and TNO155 was dissolved in 0.5% Tween 80 / 0.5% Methylcellulose / 99% Distilled water and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula from the tumor volume data on the final measurement day. The results of the in vivo antitumor activity evaluation are shown in FIG. 19. Compared with the vehicle group, the increase in tumor volume was suppressed in the compound 1 single agent administration group, the TNO155 single agent administration group, and the compound 1 and TNO155 dual agent administration group. Furthermore, in comparison between the single agent administration group and the dual agent administration group (combination group), the tumor volume was more reduced in the dual agent administration group, indicating the enhanced effect of in vivo antitumor activity by the combination of compound 1 and TNO155. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = Tumor volume after Day 0 - Tumor volume on Day 0 TV: Mean change in tumor volume in the compound 1 group, TNO155 group, or combination group CV: Mean tumor volume change in the vehicle group
[0111] Example 12: Evaluation of in vivo antitumor activity by combined use of Compound 1 and Compound 2 The in vivo antitumor activity of the combination of compound 1 and compound 2 was evaluated using xenograft models implanted with lung cancer lines NCI-H441 (KRAS-G12C) or NCI-H1373 (KRAS-G12C). Nude mice were subcutaneously injected with 5 × 10 6 The cells were transplanted and the tumor volume was 200-300 mm 3 Randomization was performed when the tumor volume reached 100 μg / mL, and administration of compound 1 and / or the combined compound was started (n=5). Compound 1 and compound 2 were orally administered once a day for 14 days. The drug dose was 3 mg / kg or 5 mg / kg for compound 1, and 0.25 mg / kg for compound 2. Compound 1 was dissolved in 10% DMSO / 5% Cremphor EL / 85% distilled water, and compound 2 was dissolved in 10% DMSO / 10% Cermphor EL / 15% PEG400 / 15% HPBCD / 50% distilled water and administered. The tumor growth inhibition rate (TGI%: Tumor Growth Inhibition%) was calculated using the following formula from the tumor volume data on the final measurement day. The results of the in vivo antitumor activity evaluation are shown in Figures 20 and 21. Compared to the vehicle group, the increase in tumor volume was suppressed in the compound 1 single agent administration group, the compound 2 single agent administration group, and the compound 1 and compound 2 dual agent administration group. Furthermore, a comparison of the single-drug administration group and the two-drug administration group (combination group) showed that the tumor volume was reduced more in the two-drug administration group, indicating that the combination of Compound 1 and Compound 2 enhanced the in vivo antitumor activity. Tumor growth inhibition rate (TGI%) = (1-TV / CV) x 100 Tumor volume (mm 3 ) = 1 / 2 x major axis (mm) x minor axis (mm) x minor axis (mm) Change in tumor volume (mm 3 ) = Tumor volume after Day 0 - Tumor volume on Day 0 TV: Mean change in tumor volume in the compound 1 group, compound 2 group, or combination group CV: Mean tumor volume change in the vehicle group
[0112] Example 13: Evaluation of in vivo RAS signal inhibitory activity by combined use of Compound 1 and Compound 2 After the in vivo antitumor activity evaluation in NCI-H441 in Example 12 was completed, compound 1 and compound 2 were re-administered to nude mice (n=3) at 5 mg / kg and 0.25 mg / kg, respectively, and the tumors were collected 4 hours later, frozen in liquid nitrogen, and stored at -80°C. The collected xenograft samples were then crushed with a multi-beads shocker (Yasui Kikai) under cooling with liquid nitrogen, and the RAS signal inhibitory activity of compound 1 and compound 2 in the xenografts was evaluated based on the same protocol as in Example 1 (in vitro RAS signal inhibitory activity evaluation). The primary antibody, secondary antibody, dilution concentration, reaction time, and reaction temperature used are shown in Tables 10 and 11. The electrophoretic image showing the results of Western blotting for the in vivo RAS signal inhibitory activity evaluation is shown in Figure 22. "KRAS-GTP" represents "KRAS" bound to GTP, and "pERK", "pAKT" and "pMEK" represent phosphorylated "ERK", "AKT" and "MEK", respectively. Compared with the use of compound 1 or compound 2 alone, the combined use of compound 1 and compound 2 reduced pERK and pMEK, indicating enhanced inhibition of MAPK signaling.
[0113] [Table 10]
[0114] [Table 11]
Claims
1. A pharmaceutical composition for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, A pharmaceutical composition, wherein the first active ingredient is a compound represented by the following formula (1) or a salt thereof, or a solvate thereof, and the second active ingredient is a molecular targeted agent: 【Chemistry 1】 。
2. A pharmaceutical composition for treating or preventing cancer, comprising a first active ingredient and used in combination with a second active ingredient, A pharmaceutical composition, wherein the first active ingredient is a molecular targeting agent, and the second active ingredient is a compound represented by the following formula (1) or a salt thereof, or a solvate thereof: 【Chemistry 2】 。
3. The pharmaceutical composition according to claim 1 or 2, wherein the first active ingredient and the second active ingredient are provided as a kit.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the first active ingredient and the second active ingredient are administered simultaneously or separately.
5. The pharmaceutical according to any one of claims 1 to 4, wherein the first active ingredient and the second active ingredient are used in combination as a combination drug.
6. The pharmaceutical agent according to any one of claims 1 to 5, wherein the molecular targeted agent is a MAPK / ERK pathway inhibitor.
7. The pharmaceutical according to any one of claims 1 to 6, wherein the molecular targeted agent is at least one selected from the group consisting of an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, and a MEK inhibitor.
8. The pharmaceutical according to any one of claims 1 to 7, wherein the molecular targeted agent is an EGFR inhibitor, a VEGF inhibitor, an SHP2 inhibitor, a KRAS-G12C inhibitor, or a MEK inhibitor.
9. The pharmaceutical according to claim 7 or 8, wherein the EGFR inhibitor is at least one selected from the group consisting of gefitinib, erlotinib, afatinib, osimertinib, lapatinib, or a salt or solvate thereof, and an anti-EGFR antibody.
10. The pharmaceutical according to any one of claims 7 to 9, wherein the EGFR inhibitor is an anti-EGFR antibody.
11. The pharmaceutical according to claim 9 or 10, wherein the anti-EGFR antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
2.
12. The pharmaceutical according to any one of claims 9 to 11, wherein the anti-EGFR antibody is cetuximab.
13. The pharmaceutical according to any one of claims 7 to 12, wherein the VEGF inhibitor is an anti-VEGF antibody.
14. The pharmaceutical according to claim 13 , wherein the anti-VEGF antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
4.
15. The pharmaceutical according to claim 13 or 14, wherein the anti-VEGF antibody is bevacizumab.
16. The medicine according to any one of claims 7 to 15, wherein the SHP2 inhibitor is at least one selected from the group consisting of RMC4550, TNO155, RLY1971, SHP099, NSC-87877, salts thereof, and solvates thereof.
17. The medicine according to any one of claims 7 to 16, wherein the SHP2 inhibitor is at least one selected from the group consisting of RMC4550, TNO155, salts thereof, and solvates thereof.
18. The medicine according to any one of claims 7 to 17, wherein the KRAS-G12C inhibitor is at least one selected from the group consisting of sotrasib, MRTX849, and salts thereof and solvates thereof.
19. The medicine according to any one of claims 7 to 18, wherein the MEK inhibitor is at least one selected from the group consisting of a compound represented by the following formula (2), trametinib, selumetinib, CH4987655, and salts thereof and solvates thereof: 【Chemistry 3】 。
20. The medicine according to any one of claims 7 to 19, wherein the MEK inhibitor is a compound represented by the following formula (2), trametinib, or a salt thereof, or a solvate thereof: 【Chemistry 4】 。
21. The pharmaceutical according to any one of claims 1 to 20, wherein the compound represented by formula (1) or a salt thereof, or a solvate thereof is a solvate of the compound represented by formula (1).
22. The pharmaceutical composition of claim 21 , wherein the solvate is a hydrate.
23. The pharmaceutical according to any one of claims 1 to 20, wherein the compound represented by formula (1) or a salt thereof, or a solvate thereof is a compound represented by formula (1).
24. The pharmaceutical composition according to any one of claims 1 to 23, wherein the cancer is a solid cancer or a blood cancer.
25. The pharmaceutical according to any one of claims 1 to 24, wherein the cancer is at least one selected from the group consisting of lung cancer, esophageal cancer, gastric cancer, colon cancer, uterine cancer, ovarian cancer, pancreatic cancer, bladder cancer, thyroid cancer, skin cancer, leukemia, malignant lymphoma, and multiple myeloma.
26. The pharmaceutical composition according to any one of claims 1 to 25, wherein the cancer is a cancer associated with an abnormality in a RAS gene or the MAPK / ERK pathway.
Citation Information
Patent Citations
Antitumor agent and antitumor effect enhancer
JP2018076369A
Leukemia therapeutic agent
JP2021063014A
Cyclic peptide compound having kras inhibiting action
WO2021090855A1
